Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is an exploratory study on the metabolic endotoxemia associated with type 2 diabetes.
The investigators will measure systemic endotoxin level and lipid level after ingestion of
high fat diet to evaluate the effect of gemigliptin, a DPP-4 inhibitor, on metabolic
endotoxemia and lipemia induced by high fat diet.